Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVOCART Disc Plus for Lumbar Disc Herniation
NCT01640457Phase 2Completed
- Sponsor
- TETEC AG
- Start
- Aug 2012
- Primary completion
- Nov 2018
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of NOVOCART Disc plus in intervertebral disc displacement and intervertebral disc degeneration (DDD) (3 arms), sponsored by TETEC AG. Primary endpoint: Oswestry Disability Index at 60 months. Started Aug 2012; status: completed.
02
Drugs
NOVOCART Disc plus
03
Conditions
intervertebral disc displacementintervertebral disc degeneration (DDD)
Beyond the preview
Go deeper on NCT01640457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640457.